TransMedics Group, Inc. (NASDAQ:TMDX) Given Consensus Rating of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has earned an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $134.80.

TMDX has been the subject of a number of recent analyst reports. Needham & Company LLC boosted their price objective on TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a report on Monday. Stifel Nicolaus initiated coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a “hold” rating and a $115.00 target price for the company. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $142.00 to $147.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an “outperform” rating and a $155.00 price target on the stock. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a report on Wednesday, October 8th.

Insider Transactions at TransMedics Group

In other news, Director David Weill sold 5,000 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total transaction of $693,200.00. Following the transaction, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. This represents a 29.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the completion of the sale, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at $2,103,235.68. The trade was a 5.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,062 shares of company stock worth $1,797,634 over the last quarter. 7.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its position in shares of TransMedics Group by 13.8% during the first quarter. PNC Financial Services Group Inc. now owns 2,294 shares of the company’s stock valued at $154,000 after buying an additional 278 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of TransMedics Group by 2.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 304,367 shares of the company’s stock worth $20,478,000 after acquiring an additional 6,934 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of TransMedics Group by 104.7% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 47,309 shares of the company’s stock worth $3,183,000 after acquiring an additional 24,200 shares in the last quarter. Nuveen LLC purchased a new stake in TransMedics Group during the first quarter valued at approximately $5,927,000. Finally, Public Sector Pension Investment Board boosted its stake in TransMedics Group by 27.4% in the first quarter. Public Sector Pension Investment Board now owns 106,480 shares of the company’s stock valued at $7,164,000 after acquiring an additional 22,894 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

NASDAQ:TMDX opened at $136.60 on Tuesday. The firm has a market capitalization of $4.67 billion, a price-to-earnings ratio of 55.30 and a beta of 2.06. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The business has a 50 day simple moving average of $125.48 and a 200-day simple moving average of $122.95. TransMedics Group has a 1 year low of $55.00 and a 1 year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s revenue was up 32.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.12 earnings per share. Equities analysts forecast that TransMedics Group will post 1 EPS for the current year.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.